Results 11 to 20 of about 75,185 (305)
Relationship between L-DOPA-induced reduction in motor and exploratory activity and degree of DAT binding in the rat [PDF]
Frontiers in Behavioral Neuroscience, 2014 Purpose: The present study assessed the influence of L-DOPA administration on neostriatal dopamine (DA) transporter (DAT) binding in relation to motor and exploratory behaviors in the rat.Methods: Rats received injections of 5 mg/kg L-DOPA, 10 mg/kg L ...
Susanne eNikolaus +7 more
doaj +2 more sources
Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats [PDF]
Brazilian Journal of Medical and Biological Research, 2010 7-Nitroindazole (7-NI) inhibits neuronal nitric oxide synthase in vivo and reduces l-DOPA-induced dyskinesias in a rat model of parkinsonism. The aim of the present study was to determine if the anti-dyskinetic effect of 7-NI was subject to tolerance ...
N. Novaretti +4 more
doaj +4 more sources
Simultaneous Determination of Levodopa and Carbidopa from Fava Bean, Green Peas and Green Beans by High Performance Liquid Gas Chromatography [PDF]
Journal of Clinical and Diagnostic Research, 2013 Introduction: According to many studies, sprouted fava beans are a rich source of levo-dihydroxy phenylalanine (L-dopa) the precursor of dopamine, and they are now being investigated for use in the management of Parkinson’s disease.
Mohseni Mehran S.M., Golshani B.
doaj +1 more source
Biosensors, 2022 Levodopa (L-Dopa) is considered to be one of the most effective therapies available for Parkinson’s disease (PD) treatment. The therapeutic window of L-Dopa is narrow due to its short half-life, and long-time L-Dopa treatment will cause some side effects
Lu Fang +9 more
doaj +1 more source
Crop Journal, 2018 Faba bean (Vicia faba L.) has been identified as a rich source of l-DOPA, which is used in treating Parkinson's disease. Biosynthesis and accumulation of active substances such as l-DOPA in plant tissues may interact with growing conditions and ...
Fatemeh Etemadi +4 more
doaj +1 more source
Frontiers in Aging Neuroscience, 2021 BackgroundIt remains unclear why patients with young-onset Parkinson’s disease more often develop levo-dihydroxyphenylalanine (L-dopa)-induced dyskinesia (LID) and have a more severe form than patients with old-onset Parkinson’s disease. Previous studies
Haruo Nishijima +8 more
doaj +1 more source
Striatal astrocytes act as a reservoir for L-DOPA.
PLoS ONE, 2014 L-DOPA is therapeutically efficacious in patients with Parkinson's disease (PD), although dopamine (DA) neurons are severely degenerated. Since cortical astrocytes express neutral amino acid transporter (LAT) and DA transporter (DAT), the uptake and ...
Masato Asanuma +4 more
doaj +1 more source
Journal of Neurology, Neurosurgery & Psychiatry, 1974 In 10 patients with Parkinsonism, treatment with L-dopa was associated with a rise in the skin conductance level and its fluctuations, an increased electromyographic activity in the frontalis muscle, and with faster reaction times. The change of skin conductance in response to a loud noise also increased and its habituation to the repetition of the ...
T B, Horvath, R A, Meares
openaire +2 more sources
Neurobiology of Disease, 2011 The therapeutic benefit of L-DOPA is commonly attributed to restoration of dopamine (DA) extracellular levels in the striatum of Parkinsonian patients. However, the loss of efficacy of L-DOPA after chronic use is paradoxically associated with a similar ...
Sylvia Navailles +3 more
doaj +1 more source
The aromatic amino acid hydroxylase genes AAH1 and AAH2 in Toxoplasma gondii contribute to transmission in the cat [PDF]
, 2017 The Toxoplasma gondii genome contains two aromatic amino acid hydroxylase genes, AAH1 and AAH2 encode proteins that produce L-DOPA, which can serve as a precursor of catecholamine neurotransmitters.
Dubey, Jitender P +3 more
core +6 more sources